PA
KALV

Parallel Advisors’s KalVista Pharmaceuticals KALV Stock Holding History

Parallel Advisors’s Portfolio KALV Stock Details KALV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-1,876
Closed -$37.8K – 4012
2026
Q1 		$37.8K Buy
1,876
+589
+46% +$9.49K ﹤0.01% 2154
2025
Q4 		$20.8K Sell
1,287
-136
-10% -$1.8K ﹤0.01% 2270
2025
Q3 		$17.3K Hold
1,423
– – ﹤0.01% 2317
2025
Q2 		$16.1K Buy
1,423
+136
+11% +$1.66K ﹤0.01% 2283
2025
Q1 		$14.9K Buy
1,287
+1,184
+1,150% +$12.1K ﹤0.01% 2280
2024
Q4 		$872 Buy
103
+35
+51% +$362 ﹤0.01% 3135
2024
Q3 		$787 Buy
+68
New +$855 ﹤0.01% 3087
2023
Q1 		– Sell
-382
Closed -$2.85K – 3463
2022
Q4 		$2.58K Buy
382
+363
+1,911% +$1.94K ﹤0.01% 2587
2022
Q3 		$0 Buy
+19
New +$266 ﹤0.01% 3333
2021
Q4 		– Sell
-8
Closed – – 3188
2021
Q3 		$0 Sell
8
-37
-82% -$750 ﹤0.01% 3170
2021
Q2 		$1K Buy
+45
New +$1.18K ﹤0.01% 2756

Other funds holding KALV

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Parallel Advisors's KALV Position: Q2 2026 in Review

Parallel Advisors sold out of KalVista Pharmaceuticals (KALV) in Q2 2026, closing a stake of 1,876 shares — an estimated $37.8K sold.

Parallel Advisors first reported a position in KALV in Q2 2021 and held it in 11 quarters. The position peaked at $37.8K in Q1 2026. 1 fund tracked by Wall St. Rank holds KALV as of Q2 2026.

  • Parallel Advisors reported no remaining KalVista Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Parallel Advisors sold 1,876 KalVista Pharmaceuticals shares in Q2 2026, an estimated $37.8K.
  • Parallel Advisors first reported a position in KalVista Pharmaceuticals in Q2 2021 and held it in 11 quarters.
  • Parallel Advisors's KalVista Pharmaceuticals position peaked at $37.8K in Q1 2026.
  • 1 fund tracked by Wall St. Rank held KalVista Pharmaceuticals as of Q2 2026.

Based on Parallel Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.